Here are four things to know.
- In the third quarter of 2016, J&J’s global sales increased by 5.9 percent, domestic sales jumped by 7.3 percent and international sales rose by 4.2 percent, excluding the net impact of acquisitions, divestitures and hepatitis C sales.
- Operational sales results jumped 4.3 percent in the third quarter of 2016, compared to the same period the year prior.
- J&J’s net earnings and diluted earnings per share for the third quarter of 2016 were $4.3 billion and $1.53, respectively, according to the report.
- J&J projects sales of $71.5 to $72.2 billion for the full 2016 year.
More articles on supply chain:
NeoGrid expands supply chain services: 3 things to know
Prescription drug costs see largest jump in 24 years
Texas Medical Center partners with J&J to develop medical devices
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.